A16AX05 - Zinc Acetate |
Not porphyrinogenic |
NP |
Mono.Rationale
There is no data indicating zinc acetate is interacting with CYP and it is therefore probably not porphyrinogenic.
Mono.ChemicalDescription
Zinc salt
Mono.TherapeuticCharacteristics
Zinc acetate is indicated for the treatment of Wilson’s disease.
Mono.MetabolismAndPharmacokinetics
Around 80% of zinc is bound to erythrocytes and the rest is mainly bound to albumin and other plasma proteins. The elimination of zinc results primarily from faecal excretion. The faecal excretion is in the greatest part due to the passage of unabsorbed zinc but it is also due to endogenous intestinal secretion.
Mono.SimilarDrugs
Mono.References
| # | Citation details | PubMed ID |
|---|---|---|
| Summary of Product Characteristics | ||
| 1. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). zinc acetate.
|
|
Mono.Tradenames
Derma Gran Spray · Galzin · Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Galzin · Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Wilzin 
Galzin · Zinc component of nano-dtpa zinc · Zinc component of nanodtpa zinc · Zinc component of nanodtpa zn-dtpa zinc 
Zinc acetate